About Oxford Immunotec
Oxford Immunotec (NASDAQ:OXFD) is a global diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions. T-SPOT is their platform technology, designed to simply and accurately examine a patient's cellular immune response to infection; the first product to come from this platform is the T-SPOT.TB Test, which is used to test for tuberculosis infection. The company's second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisition of Imugen. The T-SPOT.CMV test and the T-SPOT.PRT test are part of the Company's third product line focused on the transplantation market. In addition to these three product lines, the Company has additional active development programs in other immune-regulated conditions. On January 7th, 2021, Oxford Immunotec was acquired by PerkinElmer.
Missing: Oxford Immunotec's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Oxford Immunotec's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Oxford Immunotec
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Oxford Immunotec is included in 2 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Oxford Immunotec Patents
Oxford Immunotec has filed 6 patents.
Immunology, Immune system, Clusters of differentiation, Vaccines, Cytokines
Immunology, Immune system, Clusters of differentiation, Vaccines, Cytokines
Latest Oxford Immunotec News
Oct 31, 2022
GlobeNewswire The Global TB Diagnostics Market Size was valued at USD 1.71 billion in 2021 and the worldwide TB diagnostics market is expected to reach USD 3.01 billion by 2030. Companies Covered: Thermo Fisher Scientific Inc., Becton Dickinson and Company., Hoffmann-La Roche Ltd., Qiagen NV, BioMerieux SA, Oxford Immunotec Ltd., Cepheid Inc., Akonni Biosystems Inc., PAR Pharmaceuticals, Alere Inc. (Abbott), Lionex GmbH, Creative Diagnostics Other Prominent Key Players. New York, United States , Oct. 31, 2022 (GLOBE NEWSWIRE) -- According to a research report published by Spherical Insights & Consulting, the TB Diagnostics Market Size to grow from USD 1.71 billion in 2021 to USD 3.01 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 6.5% during the forecast period. As a direct result of this, both the government and non-profit healthcare groups have started to take new steps to stop the spread of this disease. It is important to make people more aware of how important diagnosis is if we want to increase screening and diagnosis rates, which will help the TB diagnostics industry grow. In India, for example, the Revised National Tuberculosis Control Program (RNTCP) focuses on screening for TB and giving more people access to treatment by offering free diagnostic and treatment programs. This is done to reduce the number of people who have tuberculosis. The number of diagnoses is also going up because this initiative is making it easier for the public and private sectors to work together. AD Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/1256 The COVID-19 pandemic has made an adverse impact on credit portfolios. There has been an unprecedented rise in unemployment and disruption in economic activity, putting a strain on the solvency of customers and companies. Central banks have taken a proactive approach by injecting liquidity into the market by lowering interest rates and asset purchase programs. Managing and monitoring credit, market, liquidity, and operational risk across financial markets were hard enough with ongoing geopolitical tensions, international trade wars, and the occasional hurricanes and earthquakes. The current pandemic situation has forced chief risk officers and their teams to recalibrate old assumptions and models used to manage and monitor risk. COVID-19s global impact has shown that interconnectedness plays an important role in international cooperation. As a result, many governments started rushing toward identifying, evaluating, and procuring reliable solutions powered by AI. The nucleic acid testing segment to account for the largest market size during the forecast period Based on the test type, the TB diagnostics market is categorized into Radiographic Test, Laboratory Test, Nucleic Acid Testing, Cytokine Detection Test, Drug Resistance Test, and Other Diagnostic Test Types. The nucleic acid testing segment accounts for the largest market size during the forecast period. Enzymatic amplification of bacterial DNA (or ribosomal RNA that has been translated into DNA) is followed by detection using a signal-generating probe and the right reading device. Also, you can buy several methods of enzymatic amplification in different markets around the world right now. PCR, which stands for "polymerase chain reaction," TMA, which stands for "transcription-mediated amplification," and SDA, which stands for "strand displacement amplification," are three of the most common ways to increase the amount of something. Browse key industry insights spread across 198 pages with 110 market data tables and figures & charts from the report " Global TB Diagnostics Market Size , Share, and COVID-19 Impact Analysis By Test Type (Radiographic Test, Laboratory Test, Nucleic Acid Testing, Cytokine Detection Test, Drug Resistance Test, and Other Diagnostic Test Types), By End-User (Hospital/Clinics, Diagnostics/Research Laboratory, and Other End Users), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 2030. in detail along with the table of contents. AD The hospitals/Clinics segment to account for the largest market size during the forecast period Based on the end user, the TB diagnostics market is categorized into hospitals/Clinics, Diagnostics/Research laboratories, and Other End Users. The hospitals/Clinics segment is to hold a higher CAGR during the forecast period. The Centers for Disease Control and Prevention say that more than 13 million people in the U.S. have TB that is not showing any symptoms. The number of people with MDR (multi-drug resistant) tuberculosis is expected to rise, increasing the need for diagnostic procedures in hospitals. Also, both public and private healthcare institutions and the government have started many programs to stop the spread of infectious diseases, which is expected to help this market grow. The Global TB Diagnostics Market has been segmented into five major regions: Asia-Pacific, Europe, APAC, Latin America, and MEA. North America is estimated to account for the highest market share in 2022. Because the regional market is strong, there is a growing need for advanced medical care and the use of technology and new diagnostic methods to diagnose, treat, care for, rehabilitate, and improve healthcare as a whole. There is a good chance that the market for tuberculosis diagnostics will benefit from more money going into research and development for better TB tests. There have been more and more breakthroughs in diagnosing TB, which could be the reason for the rise. Many things on the market can help find out if someone has TB. These things include everything from genetic tests done in a lab to Al for CXR interpretation. In the United States, the Centers for Disease Control and Prevention recorded a total of 7,174 cases of tuberculosis in the year 2020. Since the number of tuberculosis cases in the country is going up, the market for TB diagnostics will likely grow. Inquire Before Buying This Research Report: https://www.sphericalinsights.com/inquiry-before-buying/1256 AD AD Key Companies & Recent Developments: The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. Major vendors in the Global TB Diagnostics Market include Thermo Fisher Scientific Inc., Becton Dickinson and Company, Hoffmann-La Roche Ltd., Qiagen NV, BioMerieux SA, Oxford Immunotec Ltd., Cepheid Inc., Akonni Biosystems Inc., PAR Pharmaceutical, Alere Inc. (Abbott), Lionex GmbH, Creative Diagnostics. Browse Related Report: Global Alzheimers Disease Diagnostics and Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Therapeutics (Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Other Therapeutics), By Diagnostics (Brain Imaging and CSF Test for Alzheimers Disease), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 2030. Global Autoimmune Disease Diagnostics Market Size, Share and COVID-19 Impact Analysis By Type (Systemic Autoimmune Disease [Rheumatoid Arthritis, Psoriasis, Systemic Lupus Erythematosus (SLE), Multiple Sclerosis, Other Systemic Autoimmune Diseases and Localized Autoimmune Disease Inflammatory Bowel Disease, Type 1 Diabetes, Thyroid, and Other Localized Autoimmune Diseases]), By Diagnosis Type (Antinuclear Antibody Tests, Autoantibody Tests, Complete Blood Count (CBC), C-reactive Protein (CRP), Urinalysis and Others tests), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 2030.
Oxford Immunotec Frequently Asked Questions (FAQ)
When was Oxford Immunotec founded?
Oxford Immunotec was founded in 2002.
Where is Oxford Immunotec's headquarters?
Oxford Immunotec's headquarters is located at 115D Innovation Drive, Oxfordshire.
What is Oxford Immunotec's latest funding round?
Oxford Immunotec's latest funding round is Acq - P2P.
How much did Oxford Immunotec raise?
Oxford Immunotec raised a total of $106.35M.
Who are the investors of Oxford Immunotec?
Investors of Oxford Immunotec include PerkinElmer, Wellington Partners, Dow Venture Capital, Clarus, University of Oxford and 15 more.
Who are Oxford Immunotec's competitors?
Competitors of Oxford Immunotec include BioMarker Strategies, Novasom, Integrated Diagnostics, HyperMed Imaging, MSDx and 11 more.
Compare Oxford Immunotec to Competitors
MEC Dynamics is a medical devices company developing and manufacturing point-of-care diagnostic products, using its proprietary technology. The company's devices have been designed for use in the both physician's office as well as the patient's home. They enable the 'real time' measurement of key blood analytes for early detection and more effective management of a variety of diseases including diabetes, cardiovascular diseases and cancer. Chronic and life-threatening diseases occurring in both industrial and developing countries could be better treated through early detection and proper monitoring. MEC aims to be a global developer and manufacturer of point-of-care diagnostic products using its technology platform. MEC's lead product, AvieA1c, is FDA 510K approved and NGSP certified.
Develop and introduce highly products or systems in selected fields of veterinary and human medicine for: Diagnostic Survey, Risk Watching, Safety controls. This company offers DNA testing for traceability purposes in beef, sheep and swine, and also genetic testing for disease resistance in sheep.
Daktari Diagnostics develops products that deliver critical diagnostic information to clinicians and patients. Daktari's initial product is a handheld CD4 cell counter that aims to enable CD4 counting to be done by anyone. The company intends to bring this blood test to parts of the world where millions of people now have access to life-saving drugs, yet cannot begin treatment due to inadequate diagnostics.
CardioDynamics was incorporated in 1993 and is committed to fundamentally changing drug management with ICG. The Company's primary product, the BioZ, uses proprietary Impedance Cardiography (ICG) technology to noninvasively assess a patient's hemodynamics, data which typically has been unavailable in the physician's office and available on a limited basis in the hospital only through a time-consuming, costly, and potentially dangerous invasive procedure called Pulmonary Artery Catheterization (PAC), or the Swan Ganz Catheter. Since the BioZ's ICG monitoring is noninvasive, it can be performed in outpatient areas such as physician offices, which have never before had access to hemodynamic information in treating heart failure, high blood pressure, pacemaker, and dialysis patients. In physician offices, BioZ monitoring can decrease long term costs of hypertension management through the use of appropriate drug therapies. The reduction of blood pressure results in a decrease of more costly cardiovascular conditions including heart failure, strokes, and heart attacks. In hospitals, BioZ monitoring on surgical or intensive care patients can decrease costs through the elimination of procedure risk, reduction of hospital stay, and minimization of hospital expenditures and personnel. BioZ monitoring can also provide valuable hemodynamic information in hospital areas where previously it has not been available, such as emergency departments, critical care, step-down units, and dialysis. In this new era of cost containment, healthcare payors and providers are demanding greater efficiency and cost-effectiveness without diminishing the quality of care. The BioZ's ICG monitoring systems provide a solution to meet this growing demand.
Saladax Biomedical develops and commercializes diagnostic assays for the practical delivery of personalized medicine. The company's line of MyCare assays improves the efficacy of existing drugs through optimized dosing. Saladax's initial focus is oncology, with a portfolio of 13 chemotherapy drug dose management assays in various stages of development. Three MyCare assays are currently offered to the oncology community: My5-FU, MyPaclitaxel and MyDocetaxel. Saladax's MyCare line also serves the central nervous system (CNS) field, with two antipsychotic drug dose management assays.
Pelikan Technologies is dedicated to the development of hand-held diagnostic and monitoring devices capable of improving the screening and management of a variety of medical conditions. In addition to diabetes, the company's versatile technology platform has applications across a range of other medical conditions that involve blood screening and monitoring. Point-of-care testing and diagnostic panel test systems also represent markets that can benefit from Pelikan's technology. The Pelikan Sun can improve the quality of life for people with diabetes by combining several of the company's technologies into the most convenient and effective blood glucose self-monitoring device available. Pelikan's line of diabetes management tools will address the pain and inconvenience that has stymied the industry's manufacturers, and plagued people with diabetes, contributing to poor blood glucose monitoring compliance. By targeting these barr
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.